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A B S T R A C T
The aim of the study was to assess correlation of atherosclerosis severity as determined by two different methods of
screening for atherosclerosis: (A) measurement of the cardio-ankle vascular index-CAVI by use of the VaseraVS-1500 vas-
cular screening device, and (B) Framingham scale scoring. 52 subjects (28 male and 24 female) were enrolled in the
study. Classification of study subjects into four quartiles based on theoretically calculated 10-year risk according to
Framingham scale (medians:1%, 3%, 4% and 15%) confirmed the risk increase to be associated with a statistically sig-
nificant increase in CAVI, age and total cholesterol, and a statistically significant decrease in HDL-cholesterol (p<0.001
all). Spearman correlation coefficients showed a statistically significant correlation of 10-year risk with CAVI (p=0.0242;
r=0.4494). Study results suggested that simultaneous determination of CAVI and 10-year risk might prove justified.
They are not contradictory, the more so, these two parameters showed a significant positive correlation. This test panel
yields comprehensible, implying all the possible consequences and highly motivating information that may stimulate the
person for lifestyle modification.
Key words: cardio-ankle vascular index CAVI, atherosclerosis, Framingham scale scoring, cholesterol
Introduction
Atherosclerosis is known to be the key factor contrib-
uting significantly to the development of cardiovascular
disease as the leading cause of premature mortality, mor-
bidity and disability in the world as well as in Croatia1–4.
In European Union countries, the relative percentage of
cardiovascular disease in overall mortality is estimated
to 42%, whereas in Croatia it is even higher, with a mean
of 50.6% (female 57.9% and male 43.4%). In 2007, the
most common postmortem diagnoses were ischemic heart
disease (n=9767) and cerebrovascular disease (n=8323)4,5.
The major risk factors for cardiovascular disease de-
velopment include age, sex, elevated blood pressure, dy-
slipidemia and diabetes mellitus6–8. As some of these risk
factors can be influenced by lifestyle modification or
medicamentous therapy, timely recognition of the pres-
ence of atherosclerosis is of utmost importance9,10. This
in turn requires identification and validation of appropria-
te screening methods. Noninvasive radiological methods
such as ultrasonographic (US) measurement of arterial
wall thickness are considered as good predictors of car-
diovascular and total mortality in both hypertensive pa-
tients and general population11,12.
In the last decade, efforts have been invested in search
for a more appropriate, i.e. simpler and faster, yet reli-
able method of atherosclerotic screening. One of the at-
tempts was measuring of brachial-ankle pulse wave ve-
locity, which was indicated in the numerous studies as
reliable and reproductible predictive mark in screening
of atherosclerotic changes13,14.
But, according to the results of the compared re-
searches in the last few years, it seems that the CAVI –
cardio-ankle vascular index – recent indicator is superior
to brachial-ankle pulse wave velocity, probably primarily
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because of the fact that the latter one is subject to
changes in blood pressure (BP) during measuring15.
CAVI expressing the grade of aortic, femoral and tib-
ial artery stiffness, seems quite promising. CAVI is ob-
tained by mathematical calculation using a formula that
includes systolic and diastolic pressure values, vascular
diameter assessment and vascular diameter changes (ela-
sticity). The result obtained simultaneously for the left
and right side of the body, thus at the same time serving
as control of the measuring procedure, may help moti-
vate the patient for his/her lifestyle modification, while
providing the physician with quantitative data on the ef-
fects of different atherosclerosis risk factors. Recent stu-
dies have confirmed statistically significant positive cor-
relations of CAVI with age, hypertension, number of risk
factors present, systolic blood pressure, and some US
indicators16–18.
According to the other model proposed, the risk of
atherosclerosis is expressed as relative percentage, i.e.
the probability of undesired cardiovascular event in the
next ten years. The model has been derived from the
wide Framingham study, as the result of systematic
long-term follow up of a great number of subjects (more
than 8000). Framingham scale scoring including age,
sex, total and HDL-cholesterol concentration, systolic
blood pressure, and data on antihypertensive medica-
tion19. The aim of this study is to compare the results ob-
tained by the two models of atherosclerosis risk assess-
ment, CAVI and Framingham scale scoring and to make
correlation with other risk factors: total cholesterol and
HDL-cholesterol concentration, systolic blood pressure
and age. Such a study protocol implied indirect CAVI val-
idation performed for the first time, to the best of our
knowledge, in Europe. The search of the literature re-
vealed it to be the first study assessing the correlation of




The study included 52 subjects, 28 (54%) male and 24
(46%) female, age median 54 years. There were com-
prised persons with stable medical condition during their
regular preventive systematic check-up. Exclusion crite-
ria were history of atherosclerotic cardiovascular disease
or stroke, of heart failure or obvious heart disease, and
diabetes mellitus. This study was conducted according to
the guidelines laid down in the Declaration of Helsinki
and all procedures involving patients were approved by
the Ethics Committee of Polyclinic Sveti Rok MD. Wri-
tten informed consent was obtained from all persons.
Methods
Framingham scale scoring
We classified subjects by Framingham scale scoring
according to the theoretical risk of coronary heart dis-
ease (CHD) during 10 year time. The factors used to cal-
culate the score include age, sex, total cholestorol level,
HDL cholesterol level, systolic blood pressure, and smok-
ing habits. The final results are given in the percentage.
Determination of CAVI
CAVI was measured by the use of a Vasera VS-1500
(Fukuda Denshi, Tokyo, Japan) vascular screening de-
vice20. ECG leads are placed on the wrist; a microphone is
placed on the sternum to record heart beats; and cuffs
are placed on both arms and ankles. Data obtained by au-
tomated measurement are analyzed by the VSS-15 soft-
ware (Fukuda Denshi, Tokyo, Japan) and results are cal-
culated separately for the left and the right side of the
body. Final result is has been obtained by calculating the
mean of four consecutive measurements. It is expressed
as the parameter of stiffness, b obtained by the following
equation: b=(ln Ps/Pd)·(D/DD); in which ln Ps/Pd is nat-
ural logarithm of systolic-diastolic pressure ratio, while
DD/D is the ratio of wall extensibility.
Determination of total cholesterol
and HDL-cholesterol
Fasting blood samples were collected by use of dispos-
able vacuum system without anticoagulant (Becton Di-
ckinson, UK). Serum concentration of total cholesterol
and HDL-cholesterol was measured on a Cobas Integra
400+ (Roche Diagnostics, Basel, Switzerland) autoanaly-
zer using the reagents, calibrators and control sera of the
same manufacturer.
Statistics
Statistical data analysis was done by use of the Med-
Calc ver. 7.3.0.0 software (MedCalc Software, Mariaker-
ke, Belgium). Results on the study parameters were ex-
pressed as absolute values, median and range (25th–75th
percentile). Mann-Whitney U test was employed to com-
pare the values of all parameters between male and fe-
male subjects and for testing the presence of statistically
significant difference between L-CAVI and R-CAVI. Kru-
skal-Wallis test was used to determine the level of statis-
tical significance all of the study parameters among the
four groups according to the 10-year risk quartile. The
correlation of 10-year risk and other parameters was
tested by use of Spearman correlation.
Results
In Table 1 there are shown demographic data as well
as values of the determined and measured parameters of
all the examinees together and for male and female sepa-
rately. The value of the level of statistic significance ob-
tained by male vs. female is shown in the last right col-
umn. Fifty-two subjects (28 male and 24 female) were
enrolled in the study. Median of all the examinees age
was 54 (50 for male and 55 for female). Approximately
1/5 of the examinees of both sexes were smokers. Median
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of 10 year risk according Framingham scale scoring of all
the examinees was 7% (8 for male and 6 for female).
The above described parameters did not differ consid-
ering the sex (p values were greater than 0.05).
Numerical values of L-CAVI i D-CAVI of all the exa-
minees from 8.3. and 8.2 also did not differ by sex (p=
0.704 and p=0.489).
The concentrations of total cholesterol and HDL-cho-
lestrol (median) of all the examinees were 5.9 and 1.3
mmol/L. Statistically significant difference regarding the
sex was also not proved for those two parameters. Me-
dian of the measured systolic pressure was 125 mm Hg
for all the examinees (130 for male and 125 for female).
There has not also been found any statistically signifi-
cant difference regarding the sex.
From the total number of the examinees of both sexes
16 (31%) of them take the antihypertensive therapy
(10-ACE inhibitors, 2-beta blockers, 4-combination of
ACE inhibitors and beta blockers). Nine examinees (17%)
take statines (4-atorvastatine, 3-simvastatine, 2-fluva-
statine).
Table 2 shows results obtained by the methods of de-
scriptive statistics: median with corresponding 95% con-
fidence interval (CI), minimum, maximum and inter-
quartile range for L-CAVI and R-CAVI. The values of the
study parameters recorded were quite comparable, as
confirmed by Mann-Whitney test. Comparison of L-CAVI
and R-CAVI by Mann-Whitney test yielded no statisti-
cally significant difference (p=0.8642). In addition, test-
ing for distribution normality produced a high p-value in
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TABLE 1
DEMOGRAPHIC DATA AND STUDY PARAMETERS FOR ALL, MALE AND FEMALE WITH LEVEL OF STATISTICAL DIFFERENCE
BEETWEN SEX
Parameter All Male Female p#
Number of subjects (%) 52 (100) 28 (54) 24 (46)
*Age, yer 54 (48–52) 50 (44–56) 55 (37–58) 0.892
Number of smokers (%) 11 (21) 6 (21) 5 (21) 0.464
*Ten-year risk (%) 7 (2–11) 8 (3–15) 6 (2–9) 0.091
*L-CAVI 8.3 (7.4–8.9) 8.4 (7.6–8.8) 8.3 (7.4–8.8) 0.704
*R-CAVI 8.2 (7.4–8.9) 8.2 (7.5–8.9) 8.3 (7.3–8.9) 0.849
*Total cholesterol, mmol/L 5.9 (5.4–6.5) 5.7 (5.5–6.5) 6.1 (5.2–6.3) 0.957
*HDL-cholesterol, mmol/L 1.3 (1.0–1.7) 1.2 (1.0–1.5) 1.4 (1.0–1.7) 0.056
*Systolic blood pressure, mmHg 125 (120–140) 130 (120–140) 125 (120–135) 0.828
Number of subjects with antihypertensive therapy (%) 16 (31) 7 (25) 9 (37) 0.265
Number of subjects with statin therapy (%) 9 (17) 5 (18) 4 (17) 0.379
*results expressed as medians and ranges in parentheses (25th–75th percentile values); CAVI=cardio-ankle vascular index; L-CAVI=
left-side CAVI; R-CAVI=right-side CAVI; #level of statistical significance between male and female subjects (Mann-Whitney test)
TABLE 2
TESTING FOR STATISTICALLY SIGNIFICANT DIFFERENCE




Median (95% CI) 8.3 (7.4389–8.8900) 8.2 (7.4389–8.8611)
Interquartile range 7.375–8.852 7.575–8.930
Mann-Whitney test p=0.8642
CAVI – cardio-ankle vascular index; L-CAVI – left-side CAVI;
R-CAVI – right-side CAVI
TABLE 3
MEDIAN (MIN-MAX) OF STUDY PARAMETERS GROUPED IN QUARTILES ACCORDING TO 10-YEAR RISK VALUE WITH
CORRESPONDING LEVELS OF STATISTICAL SIGNIFICANCE AMONG GROUPS
Main criteria 10-year risk
p#
1st quartile 2nd quartile 3rd quartile 4th quartile
Ten-year risk 1 (1–1) 3 (1–4) 4 (4–8) 15 (10–16) <0.001
Age (yrs) 30 (26–59) 53 (42–58) 54 (38–65) 57 (55–61) <0.01
L-CAVI 7.6 (6.3–8.3) 8.0 (7.1–9.2) 8.1 (6.4–9.2) 8.8 (7.5–9.8) <0.01
Total cholesterol (mmol/L) 5.3 (3.9–6.9) 5.4 (4.7–6.1) 5.8 (5.5–8.9) 6.4 (6.0–8.1) <0.001
HDL-cholesterol (mmol/L) 2.1 (0.8–2.3) 1.3 (1.0–2.0) 1.3 (0.8–2.3) 1.2 (1.0–1.7) <0.001
#level of statistical significance among four quartiles (Kruskal-Wallis test)
both groups. Therefore, only results for L-CAVI are pre-
sented below, with due statistical correctness.
Table 3 shows median (range) of age, L-CAVI, total
cholesterol and HDL-cholesterol of study subjects classi-
fied according to the theoretically calculated 10-year
risk. Kruskal-Wallis test was used to test for statistically
significant differences in study parameters among the
four groups. The level of statistical significance, pre-
sented in the last column, shows the increase in the
10-year risk to be associated with a statistically signifi-
cant increase in age, L-CAVI and total cholesterol, and a
statistically significant decrease in HDL-cholesterol.
Table 4 shows statistical parameters (correlation coef-
ficient, level of statistical significance, and 95% CI of cor-
relation coefficient) obtained by correlation of 10-year
risk and L-CAVI, total cholesterol and HDL-cholesterol,
and systolic blood pressure. Ten-year risk showed signifi-
cant positive correlation with L-CAVI (r=0.4493, p=
0.0242) and systolic blood pressure (r=0.4748, p=0.0165);
borderline positive correlation with total cholesterol (p=
0.0611); and borderline negative correlation with HDL-
-cholesterol (p=0.0643).
Discussion
Recent data of the World Health Organization point
to cardiovascular disease as the leading cause of death
worldwide. In 2004, 17.1 million people died from cardio-
vascular disease in the world. The most common diagno-
ses were coronary (ischemic) heart disease and cerebro-
vascular disease. Unfortunately, the prognosis is not very
promising, suggesting a continuous rise; it is estimated
that as many as 23.6 million people will die from cardio-
vascular disease in 203021,22. Such a scenario is antici-
pated to be mainly (up to 80%) due to the epidemic of ciga-
rette smoking, inadequate physical activity, inappropri-
ate dietary habits, obesity, elevated blood pressure left
untreated, and diabetes mellitus23. As all these are signif-
icant but modifiable behavioral and environmental risk
factors, the national health authorities have focused on
their prevention. Efforts are invested to quantitatively
reduce the unfavorable prognosis, as it is likely to grow
into a huge health as well as political and socioeconomic
problem24.
It has been definitely established that atherosclerosis
greatly contributes to the development of cardiovascular
disease. The formation of atherosclerotic plaques con-
taining LDL-lipoprotein particles ingested by tissue ma-
crophages is favored by dyslipoproteinemia, i.e. excess of
total cholesterol and LDL-cholesterol, and deficiency of
atheroprotective HDL-cholesterol25,26. Irrespective of the
primary cause of oxidation (e.g., by exposure to intensive
free radical action, i.e. oxidative stress, or by the action of
excess glycation endproducts), the LDL-particle modified
by oxidation is even more prone to incorporate into the
atherosclerotic plaque in the vascular subendothelial in-
tima27,28. Vascular diameter and blood flow change with
time, along with an increase in vascular resistance and
blood pressure. The circulation hemodynamics is altered,
and laminar blood flow turns inappropriately turbulent.
These are preconditions for the formation of blood clots
that can cause gradual (thrombosis) or abrupt (embo-
lism) obstruction of the vessel and lead to undesired
outcome29. Therefore, early recognition of atherosclero-
sis and large-scale population screening for atherosclero-
sis are probably crucial in the efforts to reduce its long-
-term sequels. The screening should ideally provide clear,
reliable, widely understandable and motivating informa-
tion that will also stimulate individuals for lifestyle mod-
ifications.
CAVI is a relatively novel method of atherosclerotic
risk assessment16,30. It includes direct measurement of
systolic and diastolic blood pressure, arterial diameter
and changes in arterial diameter. CAVI result is obtained
by entering these variables in the formula. Mathema-
tically, CAVI is the product of the logarithm of systolic to
diastolic blood pressure ratio and vessel diameter to ves-
sel diameter change ratio. Final result (CAVI) is a di-
mensionless numerical index reflecting arterial condi-
tion (stiffness) from the heart to the ankle. CAVI is an
example of simple, rapid and noninvasive atherosclerotic
screening, especially since the instruments equipped
with suitable and reliable software to calculate CAVI
have become available on the market. However, these de-
vices have only been available for several years now;
therefore the relatively small number of related litera-
ture reports is quite understandable. In some studies,
CAVI was found to be appropriate not only for screening
of the general population but also in some target patient
groups with high cardiovascular morbidity, such as those
with diabetes mellitus and nephropathies31,32.
A group of authors investigated correlation between
CAVI and left ventricular (LV) diastolic dysfunction. The
grade of diastolic dysfunction was assessed by US mea-
surement of LV mass index, LV ejection fraction, left
atrium diameter, etc. Higher CAVI values were recorded
in the group of patients with reduced diastolic function.
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TABLE 4
CORRELATION OF STUDY PARAMETERS WITH 10-YEAR RISK CALCULATED
L-CAVI HDL-cholesterol Total cholesterol Systolic blood pressure
Correlation coefficient (r) 0.4493 –0.3755 0.3799 0.4748
Level of significance (p) 0.0242 0.0643 0.0611 0.0165
95% Confidence interval 0.0659–0.7171 –0.6711–0.0230 –0.0180–0.6738 0.0980–0.7325
CAVI – cardio-ankle vascular index; L-CAVI – left-side CAVI; #level of statistical significance (Spearman correlation test)
Similar to our study, they classified study subjects ac-
cording to CAVI into 4 quartiles. The percentage of pa-
tients with verified diastolic dysfunction was lowest in
the first quartile and systematically increased in each of
the next quartiles. The correlation of CAVI and grade of
LV dysfunction was explained by the multifactorial syn-
ergistic effect of aging, diabetes mellitus and hyper-
tension18. Exacerbation in terms of increased arterial
stiffness and LV diastolic dysfunction is in part attrib-
uted to the glycation endproduct effect on collagen and
elastin cross-linking, which results in structural histolo-
gic changes that may also entail functional consequen-
ces33.
Determination of LV diastolic dysfunction by tissue
Doppler US of the heart correlates better with CAVI than
classic Doppler US of the heart34.
Since CAVI as a marker of arterial stiffness is espe-
cially elevated in hypertensive patients, some authors
propose CAVI to be used in the follow up of patients tak-
ing drugs with a marked hypertensive side effect (e.g.,
sunitinib, a thyrosine kinase inhibitor with anti-angiogenic
and anti-tumor effects)35. Another study confirmed the
statistically significant correlation of CAVI with HbA1c and
homocysteine-independent markers of atherosclerosis16.
The Framingham study investigators determined the
risk of cardiovascular disease by use of a multivariable
model of logistic regression in a large number of subjects
prospectively followed-up and classified according to sex
(more than 4500 female and nearly 4000 male subjects).
The following variables were used on risk calculation:
age, sex, total cholesterol and HDL-cholesterol, smoking
habit, systolic blood pressure, and antihypertensive me-
dication19. These all are major cardiovascular risk compo-
nents, along with the parameters recorded in the study.
There are other models of risk assessment, e.g. Reynolds
risk score for women (taking in account some other bio-
medical parameters such as hsCRP and HbA1c), HEART-
SCORE, QRISK and ASSIGN, the last two including ad-
ditional family history data as compared with Framin-
gham study36–39. We decided to use the Framingham
model because the study was originally conducted in a co-
hort of Caucasian and Afro-American population, and
other studies have confirmed it to be successfully extrap-
olated to the population of Europe, Mediterranean re-
gion in particular, and Asia40.
Expressing the results of all measured variables as
quartiles of the 10-year cardiovascular risk percentage
may be perceived as the main conclusion of the present
study. Categorizing the results in quartiles based on the
key parameter value has lately been used in biomedical
statistics and we decided to employ it in the present
study18,41,42. It is an indirect method to confirm reliability
of the parameter tested. Thus, study subjects were classi-
fied in quartiles (i.e. four groups of the same number) ac-
cording to the 10-year risk percentage calculated. Cate-
gorized in this way, the results entered generated four
groups of data for each parameter, in particular those re-
ferring to CAVI. It was quite conceivable that the values
of total cholesterol, age and systolic blood pressure in-
creased, and HDL-cholesterol decreased consistently in
each of the next quartiles. This could be easily explained
by the fact that these variables influence the 10-year car-
diovascular risk in the same way since the first three pa-
rameters contribute positively and HDL-cholesterol nega-
tively to the risk score. However, the statistically signifi-
cant increase in CAVI in each of the next quartiles versus
10-year cardiovascular risk could be perceived as a result
confirming the validity of the other method.
Conclusions
Accordingly, concurrent determination of CAVI and
10-year cardiovascular risk may be considered justified.
They are not contradictory, the more so, they showed sta-
tistically significant positive correlation. This combined
methodology provides literature search, mauscript prep-
aration widely comprehensible (with all the possible con-
sequences) and individually highly motivating informa-
tion for reduce the rate off aggressive risk factors if
present, in particular dyslipidemia, hypertension and
cigarette smoking. The two methods, CAVI and 10-year
cardiovascular risk assessment, offer dual monitoring in
preliminary screening, therapy introduction or therapy
modification.
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ME\UOVISNOST CAVI, INDEKSA PROCJENE 10-GODI[NJEG RIZIKA I DRUGIH
RIZI^NIH ^IMBENIKA ATEROSKLEROZE
S A @ E T A K
U ovom radu je ispitano postojanje povezanost intenziteta ateroskleroze odre|enog pomo}u dvije razli~ite metode
aterosklerotskog screeninga: A) instrumentalnim mjerenjem cardio-ancle-vascular indeksa (CAVI) pomo}u ure|aja za
vaskularni screening Vasera VS-1500 te B) bodovanjem temeljem Framighamske skale. Sveukupno je uklju~eno 52
ispitanika (24 `ena i 28 mu{karaca). Svrstavanjem ispitanika u ~etiri istobroj~ana kvartila temeljem teoretski izra~u-
natoga 10-godi{njeg rizika prema Framigham-skoj skali (medijani: 1, 3, 4 i 15%), potvr|eno je da je njegovo pove}anje
pra}eno s statisti~ki zna~ajnim pove}anjem CAVI, dobi, koncentracije ukupnog kolesterola, uz istodobno statisti~ki
zna~ajno smanjenje HDL-kolesterola (p<0,001). Spearmanov-i koeficijenti korelacije su pokazali da 10-godi{njim rizik
statisti~ki zna~ajno pozitivno korelira s CAVI (p=0,0242; r=0,4494). Temeljem dobivenih rezultata mo`e se zaklju~iti
da istovremeno odre|ivanje CAVI indeksa te 10-godi{njeg rizika mo`e biti opravdano. Ono nije proturje~no, ~ak {tovi{e,
oni zna~ajno i pozitivno koreliraju. Na taj na~in se dobije lako razumljiva (sa svim svojim eventualnim posljedicama) i
za pojedinca visoko-motiviraju}a informacija koja }e potaknuti na promjene {tetnih ustaljenih `ivotnih navika.
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